Novartis ( NYSE: NVS) on Tuesday said that Coartem (artemether-lumefantrine) Baby has been approved by Swissmedic as the ...

Until now, infants with malaria were typically treated with tablets meant for older children, adjusted for weight, the ...

Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

Coartem Baby, which was cleared by health authorities in Switzerland, will fill an important gap in treatment. Novartis plans ...

GSK will also be responsible for success-based milestone payments as well as tiered royalties for efimosfermin owed to Novartis Pharma AG. Efimosfermin is an investigational, once-monthly subcutaneous ...

S&P Global Ratings is considering whether to reclassify Centene Corp.'s credit ratings to junk, which would strongly impact its borrowing power. Centene, the top seller of ACA health plans, is ...

Novartis has won approval in Switzerland for the world’s first malaria drug for newborns and infants, creating a new weapon ...

Novartis said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat ...

The Swiss Agency for Therapeutic Products (Swissmedic) has approved Novartis’ Coartem (artemether-lumefantrine) Baby, ...

Novartis' Coartem Baby wins Swiss approval as the first malaria drug for newborns under 5 kg, offering safer dosing and ...

The first malaria treatment for newborns and young infants has received approval from Swiss health regulators, with eight ...